Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of “Moderate Buy” by Analysts

Neurogene Inc. (NASDAQ:NGNE) has earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $44.00.

A number of brokerages have recently weighed in on NGNE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a report on Tuesday, January 13th. Canaccord Genuity Group assumed coverage on Neurogene in a research report on Friday, February 27th. They set a “buy” rating on the stock. Lifesci Capital started coverage on Neurogene in a report on Monday, January 26th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th.

Neurogene Trading Up 0.3%

Shares of Neurogene stock opened at $21.57 on Tuesday. Neurogene has a 12-month low of $6.88 and a 12-month high of $37.27. The company has a market cap of $334.12 million, a P/E ratio of -5.25 and a beta of 1.53. The company’s fifty day simple moving average is $19.11 and its two-hundred day simple moving average is $21.63.

Hedge Funds Weigh In On Neurogene

Institutional investors have recently added to or reduced their stakes in the company. Schroder Investment Management Group purchased a new stake in shares of Neurogene in the 2nd quarter worth about $451,000. PNC Financial Services Group Inc. increased its stake in shares of Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after acquiring an additional 1,232 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in Neurogene during the 3rd quarter valued at about $187,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after acquiring an additional 1,059 shares during the period. Finally, Daiwa Securities Group Inc. bought a new stake in Neurogene during the fourth quarter worth about $66,000. Institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.